|
Dr. Nivaggioli is responsible for creating and implementing the product development program for sirolimus, MacuSight's lead product candidate. Prior to joining MacuSight, Dr. Nivaggioli held the position of director of research and formulation development at Oculex Pharmaceuticals until its acquisition by Allergan in 2003. Following the acquisition, Dr. Nivaggioli was appointed to the position of senior director, drug delivery formulations by Allergan to help ensure proper transfer of Oculex's technology and intellectual property. Dr. Nivaggioli's tenure at Oculex was highlighted by his development of a new ocular drug delivery extrusion platform that was incorporated into the company's lead product, Posurdex®. Allergan has since advanced Posurdex® into Phase III clinical trials. Dr. Nivaggioli has also served as director of development in the Cygnus Drug Delivery Division of Ortho-McNeil Pharmaceutical, and prior to its acquisition by Ortho-McNeil, as Cygnus' manager of research and development. He received his Ph.D. in polymer science from the University of Toronto, his M.Sc. from the University of Bordeaux in France and his B.Sc. from the University of Paris VI. He completed his post-doctoral studies in the Department of Chemical Engineering at the Massachusetts Institute of Technology. | 